Abstract

Physical activity has many beneficial effects on metabolic disorders, such as obesity, insulin resistance, and diabetes. Meteorin-like protein (METRNL), a novel secreted protein homologous to the neurotrophin Metrn, is induced after exercise in the skeletal muscle. Herein, we investigated the effects of METRNL on lipid-mediated inflammation and insulin resistance in skeletal muscle via AMP-activated protein kinase (AMPK) or peroxisome proliferator-activated receptor δ (PPARδ). Treatment with METRNL suppressed inflammatory markers, such as nuclear factor κB (NFκB) nuclear translocation, inhibitory κBα (IκBα) phosphorylation, interleukin-6 (IL-6) expression, and pro-inflammatory cytokines (such as TNFα and MCP-1). METRNL treatment also attenuated the impaired insulin response both in palmitate-treated differentiated C2C12 cells and the skeletal muscle of high-fat diet (HFD)-fed mice. Furthermore, METRNL administration rescued glucose intolerance and reduced HFD-induced body weight gain in mice; however, METRNL did not affect calorie intake. METRNL treatment increased AMPK phosphorylation and PPARδ expression both in differentiated C2C12 cells and mouse skeletal muscle. siRNA-mediated suppression of AMPK and PPARδ abrogated the suppressive effects of METRNL on palmitate-induced inflammation and insulin resistance. Moreover, METRNL augmented the mRNA expression of fatty acid oxidation-associated genes, such as carnitine palmitoyltransferase 1 (CPT1), acyl-CoA oxidase (ACO), and fatty acid binding protein 3 (FABP3). siRNAs for AMPK and PPARδ reversed these changes. In the current study, we report for the first time that METRNL alleviates inflammation and insulin resistance and induces fatty acid oxidation through AMPK or PPARδ-dependent signaling in skeletal muscle.

Details

Title
METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice
Author
Tae Woo Jung 1 ; Lee, Sung Hoon 2 ; Hyoung-Chun, Kim 3 ; Bang, Joon Seok 4 ; Abd El-Aty, A M 5   VIAFID ORCID Logo  ; Hacımüftüoğlu, Ahmet 6 ; Shin, Yong Kyoo 7 ; Jeong, Ji Hoon 7 

 Research Administration Team, Seoul National University Bundang Hospital, Seongnam, Korea 
 College of Pharmacy, Chung-Ang University, Seoul, Korea 
 Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Chunchon, Korea 
 College of Pharmacy, Sookmyung Women’s University, Seoul, Korea 
 Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt; Department of Medical Pharmacology, Medical Faculty, Ataturk University, Erzurum, Turkey 
 Department of Medical Pharmacology, Medical Faculty, Ataturk University, Erzurum, Turkey 
 Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Korea 
Pages
1-11
Publication year
2018
Publication date
Sep 2018
Publisher
Springer Nature B.V.
ISSN
12263613
e-ISSN
20926413
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2103657823
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.